Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors.

The human intestinal absorption of 241 drugs was evaluated. Three main methods were used to determine the human intestinal absorption: bioavailability, percentage of urinary excretion of drug-related material following oral administration, and the ratio of cumulative urinary excretion of drug-related material following oral and intravenous administration. The general solvation equation developed by Abraham's group was used to model the human intestinal absorption data of 169 drugs we considered to have reliable data. The model contains five Abraham descriptors calculated by the ABSOLV program. The results show that Abraham descriptors can successfully predict human intestinal absorption if the human absorption data is carefully classified based on solubility and administration dose to humans.

[1]  Joseph P. Remington,et al.  Remington's pharmaceutical sciences , 2016 .

[2]  E. Mini,et al.  Clinical Pharmacokinetic Properties of the Macrolide Antibiotics , 2012 .

[3]  Michael H. Abraham,et al.  Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .

[4]  M. Pfeffer,et al.  Human pharmacokinetics of sotalol. , 2009, Acta pharmacologica et toxicologica.

[5]  L. Skovsted,et al.  The kinetics of propylthiouracil in hyperthyroidism. , 2009, Acta pharmacologica et toxicologica.

[6]  L. Skovsted,et al.  The pharmacokinetics of propylthiouracil. , 2009, Acta pharmacologica et toxicologica.

[7]  V. Rodighiero.  Effects of Liver Disease on Pharmacokinetics , 1999, Clinical pharmacokinetics.

[8]  J. Turgeon,et al.  Clinical Pharmacokinetics of Mexiletine , 1999, Clinical pharmacokinetics.

[9]  E. Biganzoli,et al.  Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics. , 1999, Farmaco.

[10]  S. Krämer,et al.  Absorption prediction from physicochemical parameters. , 1999, Pharmaceutical science & technology today.

[11]  M. Abraham,et al.  The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. , 1999, Journal of pharmaceutical sciences.

[12]  J. G. Douglas,et al.  Pharmacokinetic Factors in the Modern Drug Treatment of Tuberculosis , 1999, Clinical pharmacokinetics.

[13]  T. Vree,et al.  Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers. , 1999, International journal of clinical pharmacology and therapeutics.

[14]  D. E. Clark.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[15]  James A. Platts,et al.  Estimation of Molecular Linear Free Energy Relation Descriptors Using a Group Contribution Approach , 1999, J. Chem. Inf. Comput. Sci..

[16]  J. Lötsch,et al.  Pharmacokinetics of Opioids in Liver Disease , 1999, Clinical pharmacokinetics.

[17]  A. Leo,et al.  Correlation and estimation of gas-chloroform and water-chloroform partition coefficients by a linear free energy relationship method. , 1999, Journal of pharmaceutical sciences.

[18]  M. Abraham,et al.  Solute-solvent interactions in micellar electrokinetic chromatography. Characterization of sodium dodecyl sulfate-Brij 35 micellar systems for quantitative structure-activity relationship modelling. , 1999, Journal of chromatography. A.

[19]  M. Abraham,et al.  Solute-solvent interactions in micellar electrokinetic chromatography. Selectivity of lithium dodecyl sulfate-lithium perfluorooctanesulfonate mixed-micellar buffers. , 1999 .

[20]  F. Simons,et al.  Clinical Pharmacology of New Histamine H1 Receptor Antagonists , 1999, Clinical pharmacokinetics.

[21]  M. Abraham,et al.  Solute–solvent interactions in normal-phase liquid chromatography: a linear free-energy relationships study , 1999 .

[22]  N. Davies,et al.  Clinical Pharmacokinetics of Meloxicam , 1999, Clinical pharmacokinetics.

[23]  M. Abraham,et al.  Hydrogen bonding. 47. Characterization of the ethylene glycol-heptane partition system: hydrogen bond acidity and basicity of peptides. , 1999, Journal of pharmaceutical sciences.

[24]  K. Cundy.  Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir , 1999, Clinical pharmacokinetics.

[25]  H. Welker,et al.  Clinical Pharmacokinetics of Mibefradil , 1998, Clinical pharmacokinetics.

[26]  W. Curatolo,et al.  Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .

[27]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[28]  Y Zhang,et al.  Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.

[29]  R. Heinig.  Clinical Pharmacokinetics of Nisoldipine Coat-Core , 1998, Clinical pharmacokinetics.

[30]  K. Iseki,et al.  A general approach for the prediction of the intestinal absorption of drugs: regression analysis using the physicochemical properties and drug-membrane electrostatic interaction. , 1998, Journal of pharmaceutical sciences.

[31]  B. Heintz,et al.  Clinical Pharmacokinetics of Vasodilators , 1998 .

[32]  Peter C. Jurs,et al.  Prediction of Human Intestinal Absorption of Drug Compounds from Molecular Structure , 1998, J. Chem. Inf. Comput. Sci..

[33]  J. Sotelo,et al.  Pharmacokinetic Optimisation of the Treatment of Neurocysticercosis , 1998, Clinical pharmacokinetics.

[34]  Bernhard Heintz,et al.  Clinical Pharmacokinetics of Vasodilators , 1998, Clinical pharmacokinetics.

[35]  R. Sachdeo.  Topiramate. Clinical profile in epilepsy. , 1998, Clinical pharmacokinetics.

[36]  L. Denis,et al.  Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer , 1998, Clinical pharmacokinetics.

[37]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[38]  G. Koren,et al.  Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance , 1997, Clinical pharmacokinetics.

[39]  S. Troy,et al.  Pharmacokinetics and Effect of Food on The Bioavailability of Orally Administered Venlafaxine , 1997, Journal of clinical pharmacology.

[40]  R. Barbhaiya,et al.  Clinical Pharmacokinetics of Nefazodone , 1997, Clinical pharmacokinetics.

[41]  N. Davies,et al.  Clinical Pharmacokinetics of Diclofenac , 1997, Clinical pharmacokinetics.

[42]  N. Davies,et al.  Clinical Pharmacokinetics of Sulindac , 1997, Clinical pharmacokinetics.

[43]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[44]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[45]  A. Harrower.  Pharmacokinetics of Oral Antihyperglycaemic Agents in Patients with Renal Insufficiency , 1996, Clinical pharmacokinetics.

[46]  K. S. Gill,et al.  The Clinical Pharmacokinetics of Famciclovir , 1996, Clinical pharmacokinetics.

[47]  C. Binnie,et al.  Clinical Pharmacokinetics of Newer Antiepileptic Drugs , 1996, Clinical pharmacokinetics.

[48]  Leslie Z. Benet,et al.  Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery , 1996 .

[49]  A. Scheen.  Clinical Pharmacokinetics of Metformin , 1996, Clinical pharmacokinetics.

[50]  E. Acosta,et al.  Clinical Pharmacokinetics of Zidovudine , 1996, Clinical pharmacokinetics.

[51]  Robert S. Boethling,et al.  Improved method for estimating water solubility from octanol/water partition coefficient , 1996 .

[52]  R. Amrein,et al.  Pharmacology of flumazenil , 1995, Acta anaesthesiologica Scandinavica. Supplementum.

[53]  A. Favero,et al.  Ondansetron Clinical Pharmacokinetics , 1995, Clinical pharmacokinetics.

[54]  L. Benet,et al.  The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.

[55]  J. Benítez,et al.  Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[56]  K. Wilner,et al.  Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects. , 1995, British journal of clinical pharmacology.

[57]  A. K. Scott.  Sumatriptan Clinical Pharmacokinetics , 1994, Clinical pharmacokinetics.

[58]  H. Lennernäs,et al.  Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. , 1994, British journal of clinical pharmacology.

[59]  A. Taburet,et al.  Pharmacokinetic Optimisation of Asthma Treatment , 1994, Clinical pharmacokinetics.

[60]  M. Mattila,et al.  Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents , 1994, Clinical pharmacokinetics.

[61]  D. Morris,et al.  Azithromycin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.

[62]  P. Meredith,et al.  Enalapril Clinical Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships , 1993, Clinical pharmacokinetics.

[63]  W. Jusko,et al.  Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.

[64]  M. Tarbit,et al.  Disposition of sumatriptan in laboratory animals and humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[65]  J. Hanyok.  Clinical pharmacokinetics of sotalol. , 1993, The American journal of cardiology.

[66]  A. Fahr.  Cyclosporin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.

[67]  R. Oberbauer,et al.  Pharmacokinetics of Indomethacin in the Elderly , 1993, Clinical pharmacokinetics.

[68]  M. Shelton,et al.  Comparative Pharmacokinetics of Antiviral Nucleoside Analogues , 1993, Clinical pharmacokinetics.

[69]  F. Jamali,et al.  Clinical Pharmacokinetics of Ketorolac Tromethamine , 1992, Clinical pharmacokinetics.

[70]  D. Crommelin,et al.  Liposomal and Lipid Formulations of Amphotericin B , 1992, Clinical pharmacokinetics.

[71]  M. Shannon,et al.  Pharmacokinetics of Drugs in Overdose , 1992, Clinical pharmacokinetics.

[72]  F. Tse,et al.  Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.

[73]  K. Desante,et al.  Pharmacokinetic Profile of Loracarbef , 1992, The American journal of medicine.

[74]  K. Goa,et al.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. , 1991, Drugs.

[75]  P. Hinderling,et al.  Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy Humans , 1991, Therapeutic drug monitoring.

[76]  W. Hayton,et al.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children , 1991, Antimicrobial Agents and Chemotherapy.

[77]  K. Kripalani,et al.  Pharmacokinetics of fosinopril in patients with various degrees of renal function , 1991, Clinical pharmacology and therapeutics.

[78]  D. Back,et al.  The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. , 1991, Contraception.

[79]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[80]  J. Kelly,et al.  Clinical Pharmacokinetics of the Newer ACE Inhibitors , 1990, Clinical pharmacokinetics.

[81]  J. Scatina,et al.  Excretion and metabolism of recainam, a new anti-arrhythmic drug, in laboratory animals and humans. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[82]  F. Jamali,et al.  Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers , 1990, Clinical pharmacokinetics.

[83]  P. Burrows,et al.  Simultaneous assessment of intestinal permeability and lactose tolerance with orally administered raffinose, lactose and L-arabinose. , 1990, Clinical science.

[84]  D. Tepper,et al.  Betaxolol: A New Long‐Acting Beta1‐Selective Adrenergic Blocker , 1990, Journal of clinical pharmacology.

[85]  D. Breimer,et al.  Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. , 1990, British journal of clinical pharmacology.

[86]  J. Rask-Madsen,et al.  Clinical Pharmacokinetics of Drugs Used in the Treatment of Gastrointestinal Diseases (Part I) , 1990, Clinical pharmacokinetics.

[87]  F. Sallee,et al.  Clinical Pharmacokinetics of Imipramine and Desipramine , 1990, Clinical pharmacokinetics.

[88]  D. Morgan,et al.  Clinical Pharmacokinetics of β-Agonists , 1990 .

[89]  S. Singhvi,et al.  Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. , 1990, British journal of clinical pharmacology.

[90]  C. Adithan,et al.  Differential effect of type I and type II diabetes mellitus on serum ampicillin levels. , 1989, International journal of clinical pharmacology, therapy, and toxicology.

[91]  D. McTavish,et al.  Verapamil , 2012, Drugs.

[92]  A G Renwick,et al.  The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. , 1989, British journal of clinical pharmacology.

[93]  Sietsema Wk,et al.  The absolute oral bioavailability of selected drugs , 1989 .

[94]  E. Mini,et al.  Clinical Pharmacokinetic Properties of the Macrolide Antibiotics , 1989, Clinical pharmacokinetics.

[95]  H. Ahr,et al.  Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. , 1989, Arzneimittel-Forschung.

[96]  I. Chen,et al.  The physiological disposition of lovastatin. , 1989, Drug Metabolism And Disposition.

[97]  T. Staks,et al.  Pharmacokinetics of 3H-cicaprost in healthy volunteers. , 1989, Prostaglandins.

[98]  D. Greenblatt,et al.  Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam , 1988, Journal of clinical pharmacology.

[99]  A. Karlsson,et al.  Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus , 1988, Clinical pharmacology and therapeutics.

[100]  C. Haanen,et al.  Clinical Pharmacokinetics of Doxorubicin , 1988, Clinical pharmacokinetics.

[101]  A. Arancibia,et al.  Dose-dependent bioavailability of amoxycillin. , 1988, International journal of clinical pharmacology, therapy, and toxicology.

[102]  P. A. Todd,et al.  Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. , 1988, Drugs.

[103]  D. Lowenthal,et al.  Clinical Pharmacokinetics of Clonidine , 1988, Clinical pharmacokinetics.

[104]  R. Woestenborghs,et al.  Excretion and biotransformation of cisapride in dogs and humans after oral administration. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[105]  B. H. Migdalof,et al.  Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases , 1988, Clinical pharmacokinetics.

[106]  H. Mattie.  Clinical Pharmacokinetics of Aztreonam , 1988, Clinical pharmacokinetics.

[107]  A. Christophersen,et al.  Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. , 1987, Pharmacology & toxicology.

[108]  M. Eichelbaum,et al.  Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. , 1987, British journal of clinical pharmacology.

[109]  A. Finn,et al.  Effect of dose and food on the bioavailability of cefuroxime axetil. , 1987, Biopharmaceutics & drug disposition.

[110]  M. Jacobson,et al.  Human pharmacokinetics and tolerance of oral ganciclovir , 1987, Antimicrobial Agents and Chemotherapy.

[111]  S. Clissold,et al.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. , 1987, Drugs.

[112]  G. Stein.  Review of the bioavailability and pharmacokinetics of oral norfloxacin. , 1987, The American journal of medicine.

[113]  H. Rogers,et al.  Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. , 1987, British journal of clinical pharmacology.

[114]  M. Slevin,et al.  The Clinical Pharmacology of Etoposide and Teniposide , 1987, Clinical pharmacokinetics.

[115]  S. Broder,et al.  Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases , 1987, Clinical pharmacology and therapeutics.

[116]  N. Holford.  Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.

[117]  G. Drusano,et al.  Absolute oral bioavailability of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.

[118]  T. Peters,et al.  Lactulose 51Cr-labelled ethylenediaminetetra-acetate, l-rhamnose and polyethyleneglycol 500 as probe markers for assessment in vivo of human intestinal permeability , 1986 .

[119]  E. Dejana,et al.  Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. , 1986, International journal of clinical pharmacology, therapy, and toxicology.

[120]  R. Sonders.  Pharmacokinetics of terazosin. , 1986, The American journal of medicine.

[121]  R. Heel,et al.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. , 1986, Drugs.

[122]  B. Huitfeldt,et al.  Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. , 1986, British journal of clinical pharmacology.

[123]  R. N. Brogden,et al.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. , 1985, Drugs.

[124]  D. Paton,et al.  Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines) , 1985, Clinical pharmacokinetics.

[125]  R. Cody,et al.  Clinical Pharmacokinetics of the Angiotensin Converting Enzyme Inhibitors , 1985, Clinical pharmacokinetics.

[126]  D. Westerlund,et al.  Dose‐dependent absorption of amoxycillin and bacampicillin , 1985, Clinical pharmacology and therapeutics.

[127]  C. Regårdh,et al.  Felodipine kinetics in healthy men , 1985, Clinical pharmacology and therapeutics.

[128]  W. Rapeport.  Clinical Pharmacokinetics of Bretylium , 1985, Clinical pharmacokinetics.

[129]  G. Amidon,et al.  Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.

[130]  R. Day,et al.  Stereoselective disposition of ibuprofen enantiomers in infants. , 1985 .

[131]  P. Welling,et al.  A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures. , 1985, Biopharmaceutics & drug disposition.

[132]  P. Meredith,et al.  Clinical Pharmacokinetics of Prazosin — 1985 , 1985, Clinical pharmacokinetics.

[133]  M. Holdiness,et al.  Clinical Pharmacokinetics of the Antituberculosis Drugs , 1984, Clinical pharmacokinetics.

[134]  S. Ukabam,et al.  Small intestinal permeability to mannitol, lactulose, and polyethylene glycol 400 in celiac disease , 1984, Digestive diseases and sciences.

[135]  P. Ambrose.  Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate , 1984, Clinical pharmacokinetics.

[136]  M. Pfeffer,et al.  Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine , 1983, Antimicrobial Agents and Chemotherapy.

[137]  S. Anderson,et al.  Azosemide kinetics and dynamics , 1983, Clinical pharmacology and therapeutics.

[138]  R. N. Brogden,et al.  Guanabenz , 1983, Drugs.

[139]  O. Laskin.  Clinical Pharmacokinetics of Acyclovir , 1983, Clinical pharmacokinetics.

[140]  M. Stern,et al.  Oral bioavailability of the monobactam aztreonam (SQ 26,776) in healthy subjects , 1983, Antimicrobial Agents and Chemotherapy.

[141]  J. Schornagel,et al.  The clinical pharmacology of methotrexate. , 1983, Cancer treatment reviews.

[142]  J. Biollaz,et al.  Enalapril maleate and a lysine analogue (MK-521): disposition in man. , 1982, British journal of clinical pharmacology.

[143]  J. Meier.  Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. , 1982, American heart journal.

[144]  P. Welling,et al.  Bioavailability of chlorothiazide from 50, 100, and 250 MG solution doses. , 1982, Biopharmaceutics & drug disposition.

[145]  J. Clements,et al.  Clinical Pharmacokinetics of Paracetamol , 1982, Clinical pharmacokinetics.

[146]  S. Yung,et al.  Ascorbic acid absorption in humans: a comparison among several dosage forms. , 1982, Journal of pharmaceutical sciences.

[147]  M. Sugiyama,et al.  Fosfomycin kinetics after intravenous and oral administration to human volunteers , 1981, Antimicrobial Agents and Chemotherapy.

[148]  H Connor,et al.  Metformin kinetics in healthy subjects and in patients with diabetes mellitus. , 1981, British journal of clinical pharmacology.

[149]  P. Schechter,et al.  Kinetics of α‐difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase , 1981, Clinical pharmacology and therapeutics.

[150]  Y. Kasuya,et al.  Absorption, metabolism, and excretion of oral testosterone in humans by mass fragmentography. , 1980, The Journal of clinical endocrinology and metabolism.

[151]  M. Hümpel,et al.  Kinetics and biotransformation of lormetazepam , 1980 .

[152]  D. Perrier,et al.  Effect of dose on phenytoin absorption , 1980, Clinical pharmacology and therapeutics.

[153]  C. Filer,et al.  The metabolism of carfecillin in rat, dog and man. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[154]  J. Cruickshank.  The clinical importance of cardioselectivity and lipophilicity in beta blockers. , 1980, American heart journal.

[155]  S. Singhvi,et al.  Disposition of captopril in normal subjects , 1980, Clinical pharmacology and therapeutics.

[156]  F. de Pablo,et al.  Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy. , 1979, International journal of clinical pharmacology and biopharmacy.

[157]  H. Pieniaszek,et al.  Relative Systemic Availability of Sulfapyridine from Commercial Enteric‐Coated and Uncoated Sulfasalazine Tablets , 1979, Journal of clinical pharmacology.

[158]  W. Bleyer.  The clinical pharmacology of methotrexate. new applications of an old drug , 1978, Cancer.

[159]  L. Benet,et al.  Kinetics of oral ethambutol in the normal subject , 1977, Clinical pharmacology and therapeutics.

[160]  D. Greenblatt,et al.  Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. , 1977, The Journal of pharmacology and experimental therapeutics.

[161]  U. Klotz,et al.  Pharmacokinetics and bioavailability of sodium valproate , 1977, Clinical pharmacology and therapeutics.

[162]  C. Dollery,et al.  Pharmacokinetics and concentration‐effect relationships of intravenous and oral clonidine , 1977, Clinical pharmacology and therapeutics.

[163]  P. Neuvonen,et al.  Fate of [14C]-bumetanide in man. , 1977, British journal of clinical pharmacology.

[164]  R. L. Vann,et al.  Pharmacokinetics of Amoxicillin: Dose Dependence After Intravenous, Oral, and Intramuscular Administration , 1977, Antimicrobial Agents and Chemotherapy.

[165]  J. Hengstmann,et al.  Metabolism and pharmacokinetics of orciprenaline in various animal species and man. , 1976, Archives internationales de pharmacodynamie et de therapie.

[166]  R. DeJager,et al.  Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans. , 1975, Cancer research.

[167]  I. Strøyer,et al.  Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease. , 1975, Cancer chemotherapy reports.

[168]  D. Tocco,et al.  Physiological disposition and metabolism of timolol in man and laboratory animals. , 1975, Drug metabolism and disposition: the biological fate of chemicals.

[169]  C. Ditzler,et al.  Bioavailability of oral dexamethasone , 1975, Clinical pharmacology and therapeutics.

[170]  P. Bayliss,et al.  Blood level studies with viloxazine hydrochloride in man. , 1975, British journal of clinical pharmacology.

[171]  A. Sedaghat,et al.  Lack of Effect of Cholestyramine on the Pharmacokinetics of Clofibrate in Man , 1975, European journal of clinical investigation.

[172]  K. Hellström,et al.  Absorption and decomposition of potassium‐35S‐phenoxymethyl penicillin , 1974, Clinical pharmacology and therapeutics.

[173]  H. G. Morgan,et al.  Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure , 1974, Clinical pharmacology and therapeutics.

[174]  L. Hellman,et al.  Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. , 1973, The Journal of pharmacology and experimental therapeutics.

[175]  G. Bodem,et al.  Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man , 1973, Clinical pharmacology and therapeutics.

[176]  W. Pollmann,et al.  [Comparative pharmacokinetic studies on fenoterol-hydrobromide in rat, dog and man]. , 1972, Arzneimittel-Forschung.

[177]  S. Walker,et al.  The absorption, excretion and metabolism of disodium (14C)cromoglycate in man. , 1971, The Biochemical journal.

[178]  A. Smith,et al.  Absorption, distribution and elimination of 14 C-amiloride in normal human subjects. , 1971, British journal of pharmacology.

[179]  R. Johansson,et al.  Absorption of alprenolol in man from tablets with different rates of release. , 1971, Acta pharmaceutica Suecica.

[180]  Schwartz De,et al.  Assay and pharmacokinetics of trimethoprim in man and animals. , 1969 .

[181]  L. A. Stone,et al.  Computer Aided Design of Experiments , 1969 .

[182]  Malcolm Rowland,et al.  Pharmacokinetics of Acetylsalicylic Acid and Salicylic Acid After Intravenous Administration in Man , 1968 .

[183]  H. Schedl.  Absorption of steroid hormones from the human small intestine. , 1965, The Journal of clinical endocrinology and metabolism.

[184]  E. Henderson,et al.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. , 1965, Cancer research.

[185]  J. Kirsner,et al.  Absorption and Excretion of 1,2,H3-Hydrocortisone in Regional Enteritis and Ulcerative Colitis, with a Note on Hydrocortisone Production Rates , 1963 .

[186]  T. Chalmers,et al.  Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease. , 1960, The New England journal of medicine.

[187]  A. Vermeulen.  The metabolism of 4-14C prednisolone. , 1959, The Journal of endocrinology.

[188]  R. E. Peterson,et al.  The physiological disposition and metabolic fate of hydrocortisone in man. , 1955, The Journal of clinical investigation.

[189]  A. Glazko,et al.  BIOCHEMICAL STUDIES ON CHLORAMPHENICOL (CHLOROMYCETIN): II. Tissue Distribution and Excretion Studies , 1949 .

[190]  A. Glazko,et al.  BIOCHEMICAL STUDIES ON CHLORAMPHENICOL (CHLOROMYCETIN) , 1949 .

[191]  L. Goodman,et al.  THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .

[192]  J. Platts,et al.  Partition of Volatile Organic Compounds from Air and from Water into Plant Cuticular Matrix: An LFER Analysis , 2000 .

[193]  James A. Platts,et al.  Estimation of Molecular Linear Free Energy Relationship Descriptors by a Group Contribution Approach. 2. Prediction of Partition Coefficients , 2000, J. Chem. Inf. Comput. Sci..

[194]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[195]  G. E. Pakes,et al.  Clinical Pharmacokinetics of Lamivudine , 1999, Clinical pharmacokinetics.

[196]  Michael H. Abraham,et al.  Hydrogen bonding part 46: a review of the correlation and prediction of transport properties by an lfer method: physicochemical properties, brain penetration and skin permeability , 1999 .

[197]  K. Luthman,et al.  Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.

[198]  M. Walker,et al.  Clinical pharmacokinetics of new antiepileptic drugs. , 1995, Pharmacology & therapeutics.

[199]  L. Wiseman,et al.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. , 1994, Drugs.

[200]  G L Amidon,et al.  Absorption of peptide and peptidomimetic drugs. , 1994, Annual review of pharmacology and toxicology.

[201]  R. Haddock,et al.  Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[202]  D. Debruyne,et al.  Clinical Pharmacokinetics of Fluconazole , 1993, Clinical pharmacokinetics.

[203]  D. Murdoch,et al.  Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. , 1992, Drugs.

[204]  F. Bressolle,et al.  Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. , 1992, Journal of pharmaceutical sciences.

[205]  D. Jack.  Handbook of Clinical Pharmacokinetic Data , 1992, Palgrave Macmillan UK.

[206]  O. Keene,et al.  The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. , 1991, European neurology.

[207]  K. Lasseter,et al.  The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[208]  P. Glare,et al.  Clinical pharmacokinetics of morphine. , 1991, Therapeutic drug monitoring.

[209]  K. Lauritsen,et al.  Clinical pharmacolinetics of drugs used in the treatment of gastrointestinal diseases. I , 1990 .

[210]  U. Stephan,et al.  Pharmacokinetic Disposition of Quinolones in Human Body Fluids and Tissues , 1989, Clinical pharmacokinetics.

[211]  J. Paulson,et al.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. , 1989, British journal of clinical pharmacology.

[212]  E. Sellers,et al.  Clinical Pharmacokinetics of Non-Opiate Abused Drugs , 1989, Clinical pharmacokinetics.

[213]  F. Merkus,et al.  THE METABOLISM AND BIOPHARMACEUTICS OF SPIRONOLACTONE IN MAN , 1987, Reviews on drug metabolism and drug interactions.

[214]  T. Prueksaritanont,et al.  Absorption of iothalamate after oral administration: a preliminary study in humans and interspecies differences. , 1987, Biopharmaceutics & drug disposition.

[215]  S. Yamada,et al.  Absorption, distribution and excretion of sultopride in man and several animal species. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.

[216]  K. Jauhiainen,et al.  The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study. , 1985, European urology.

[217]  M. Sugiyama,et al.  Species differences in the disposition and metabolism of camazepam. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.

[218]  M. Cayen.  Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. , 1985, Pharmacology & therapeutics.

[219]  Frey Fj,et al.  Systemic availability of prednisolone following oral administration of prednisone , 1984 .

[220]  J. Brien,et al.  Disposition and pharmacokinetics of disulfiram and calcium carbimide (calcium cyanamide). , 1983, Drug metabolism reviews.

[221]  E. Ulm.  Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. , 1983, Drug metabolism reviews.

[222]  S. Ukabam,et al.  Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. , 1983, Digestion.

[223]  D. Adam,et al.  [Pharmacokinetics of ceftizoxime with and without probenecid]. , 1982, Arzneimittel-Forschung.

[224]  M. Eichelbaum,et al.  Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. , 1982, Arzneimittel-Forschung.

[225]  R. Schilsky,et al.  Clinical pharmacology of methotrexate. , 1981, Cancer treatment reports.

[226]  A. Renwick,et al.  The pharmacokinetics of saccharin in man. , 1981, Xenobiotica; the fate of foreign compounds in biological systems.

[227]  D. Lowenthal.  Pharmacokinetics of Clonidine , 1980, Journal of cardiovascular pharmacology.

[228]  J. M. Shaw,et al.  Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: an unusual species difference. , 1978, Xenobiotica; the fate of foreign compounds in biological systems.

[229]  S. Garattini,et al.  Clinical Pharmacokinetics of Diazepam , 1978, Clinical pharmacokinetics.

[230]  K. Shimizu.  Fosfomycin: Absorption and excretion. , 1977, Chemotherapy.

[231]  M. Barza,et al.  Pharmacokinetics of the Penicillins in Man , 1976, Clinical pharmacokinetics.

[232]  D. M. Ryan,et al.  Cefuroxime - a new cephalosporin antibiotic. , 1976, The Journal of antibiotics.

[233]  G. Shenfield,et al.  The Pharmacokinetics of Rimiterol in Man , 1974 .

[234]  K. Florey,et al.  Analytical profiles of drug substances , 1972 .

[235]  K. Hellström,et al.  The gastrointestinal absorption of atropine in man. , 1971, Clinical science.